Tirzepatide in direct comparisons

GIP and GLP-1

Tirzepatide is a synthetic peptide based mainly on GIP, another gut hormone. A fatty part helps it bind albumin and stay in circulation. It activates both GIP and GLP-1 receptors, which participate in the body's response to meals. A clinical reference describes its dual-receptor pharmacology.

The effects include glucose-dependent insulin release, reduced inappropriate glucagon release, slower gastric emptying and reduced appetite and food intake. I admire tirzepatide’s dual design because it puts two receptor activities into one peptide. Its practical value becomes clearer in comparisons where people received specified treatments and researchers measured their outcomes.

Approved uses include type 2 diabetes, chronic weight management and moderate to severe obstructive sleep apnea in adults with obesity. That approval concerns particular finished medicines and indications. Compounded medicines are not FDA-approved.

SURMOUNT-1

SURMOUNT-1 enrolled 2,539 adults without diabetes who had obesity, or overweight with a weight-related complication. At 72 weeks, mean weight changes across the three tirzepatide treatment groups were −15.0%, −19.5% and −20.9%, compared with −3.1% for placebo.

The most common adverse events were gastrointestinal, mostly mild to moderate and concentrated during treatment escalation. I take the large weight changes seriously, alongside the difficulty some participants had tolerating treatment.

SURMOUNT-5: the semaglutide comparison

In the SURMOUNT-5 trial, 751 adults with obesity and without type 2 diabetes were assigned tirzepatide or semaglutide. At 72 weeks, mean body-weight change was −20.2% with tirzepatide and −13.7% with semaglutide. The difference was statistically significant.

This was an open-label study, meaning participants knew their assigned medicine. The comparison used the maximum tolerated treatments specified by the trial. It establishes a difference in average weight change under those conditions; it leaves separate cardiovascular and kidney questions to studies designed to measure them.

The diabetes comparison

SURPASS-2 followed 1,879 adults with type 2 diabetes for 40 weeks. Tirzepatide produced greater reductions in glycated haemoglobin, a measure of longer-term blood sugar, and greater weight reductions than the semaglutide treatment used in that trial.

The diabetes and obesity comparisons used different populations and treatment conditions. Taken together, they establish substantial human effects while leaving room for different answers about other illnesses. Semaglutide's cardiovascular and kidney trials remain relevant on their own terms.

Gallbladder, pancreas and tolerability

A review combining nine randomized trials found a higher risk for the combined outcome of gallbladder or biliary disease. The individual components did not each show a significant increase. The same review did not establish a statistically significant increase in pancreatitis, leaving uncertainty about that risk.

The clinical reference describes the boxed warning about thyroid C-cell tumours, which is based on rodent findings. Whether that risk applies to people remains unestablished. Digestive adverse effects feature prominently in the major diabetes trial and the placebo-controlled obesity trial.

People outside trials describe quieter appetite, changes in home glucose readings, more energy and easier movement, along with constipation, diarrhea, nausea, sulfur-smelling burps, low energy, altered taste and hair shedding. Those are anecdotal reports, not clinical evidence. Accounts of muscle loss or a weight plateau also need more than an individual impression to establish cause.

For the comparison of mixtures and binding partners, the striking difference is how far this medicine has progressed into patient testing. KPV's carrier experiments and GHK-Cu's skin studies address earlier, narrower questions.